Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
FierceBiotech3d
Vertex posts full pain data ahead of FDA ruling, unpacking combo results, Vicodin miss and stellar safety
Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid ...
BioSpace3d
Vertex Unveils Full Phase III Data for Non-Opioid Pain Candidate, Touts Safety Profile
BMO Capital Markets analyst Evan Seigerman in a note to investors said the late-stage data for Vertex’s experimental ...
Business Wire6d
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on ...
The Pharma Letter3d
Vertex says Phase III data highlight suzetrigine’s potential
Vertex Pharmaceuticals on Sunday presented its pivotal Phase III data on suzetrigine, an investigational, oral, highly ...
Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Vertex's diverse pipeline positions it for a growth, despite challenges in launching new drugs like Casgevy and suzetrigine.
Vertex Pharmaceuticals’ Suzetrigine: A Promising Non-Opioid Solution to Acute Pain Management
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Vertex Pharmaceuticals: Strategic Growth and Promising Drug Development Drive Buy Rating
J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating on October 17. Jessica Fye has given ...
Vertex coverage resumed by UBS at buy on growth potential
UBS has resumed coverage of Vertex Pharmaceuticals (NASDAQ:VRTX) with a buy rating, citing the company's growth potential.
Investing6d
Vertex to present suzetrigine phase 3 data at ASA meeting
BOSTON - Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ:VRTX) is set to present pivotal Phase 3 data on suzetrigine, an investigational non-opioid pain signal inhibitor, at the American ...
Investing2d
Vertex shares maintain Sell rating from Canaccord Genuity
Canaccord Genuity has maintained its Sell rating and $361.00 price target on Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX), following an investor event focused on the company's pain ...
Investing6d
Vertex to present suzetrigine phase 3 data at ASA meeting
BOSTON - Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ:VRTX) is set to present pivotal Phase 3 data on suzetrigine, an investigational non-opioid pain signal inhibitor, at the American ...